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The p53 tumor suppressor is a critical transcription factor for controlling cell growth and apoptosis during 
times of cellular stress. In this issue of Cancer Cell, Lain et al. have used a p53-responsive reporter gene 
as the readout for screening small-molecule activators of p53 that could potentially reduce tumor growth. 
Using this approach, tenovin-6 was identified as a potent SIRT1 and SIRT2 inhibitor that indirectly activated 
p53 at single-digit micromolar concentrations. The identification of a specific sirtuin inhibitor has broad 
implications in understanding sirtuin-p53 signaling and the development of novel chemotherapeutics.The use of in vitro biochemical screening 
has been the traditional approach for drug 
discovery for a number of years. Structural 
activity relationship (SAR) studies and 
applied theories such as Lipinski’s “Rule 
of Five” are often used to guide medicinal 
chemistry to further develop these leads 
into “drug-like” compounds (Keller et al., 
2006). Advancing compound screens 
directly to mammalian cell culture-based 
assays through the forward chemical 
genetics approach bypasses an initial 
biochemical screen and offers several 
advantages for development of hit com-
pounds (Lokey, 2003). For example, the 
concentration of a hit compound identified 
using a mammalian cell-based screen is 
oftentimes the desired concentration for 
further in vivo analysis. In addition, use 
of a signaling pathway reporter system 
as a functional readout in combination 
with appropriate control assays can gen-
erally eliminate compounds that cause 
global cytotoxicity from potential hits. A 
major drawback of this type of approach 
resides in identifying the mechanism of 
action for a hit compound because sev-
eral mechanisms can result in the desired 
cellular phenotype.
By using the well-characterized p53 
pathway with defined transcriptional 
targets, Lain et al. have recently identi-
fied a small-molecule activator of p53 at 
single-digit micromolar concentrations 
and generated its derivatives (Lain et 
al., 2008). Furthermore, Lain et al. have 
defined the specific mechanism of action 
for these compounds and shown com-
parable potencies in both mammalian 
cell-based assays and highly aggressive 
melanoma xenograft tumors.The p53 tumor suppressor is a well-
characterized transcription factor that 
responds to a large variety of cellular 
stresses (Brooks and Gu, 2003). Using 
a p53-regulated reporter system, the 
authors identified a hit compound called 
tenovin-1 that reversibly increased p53 
and p21CIP/WAF1 protein levels and 
decreased cellular growth in a panel of 
tumor cell lines tested. Additional obser-
vations suggested that the compound 
did not activate p53 indirectly through 
activation of a DNA damage response 
because it did not induce phosphoryla-
tion of p53 serine 15 or H2AX. The poor 
water solubility of tenovin-1 led to SAR 
studies and the development of a more 
water-soluble derivative, tenovin-6, that 
also had a slightly increased potency in 
p53 activation. Interestingly, although a 
functional p53 protein contributed to the 
growth inhibition of tumor cell lines both 
in vivo and in vitro by tenovins, it was not 
essential for the long-term killing effect. 
This suggested that tenovins targeted a 
factor or factors upstream of p53 that 
may affect other pathways of the cell 
growth circuitry.
To identify the target of tenovins, the 
authors screened a collection of diploid 
S. cerevisiae strains containing heterozy-
gous deletions that together covered 
over 94% of the protein-coding genes 
and identified SIR2 as a tenovin-6 tar-
get. SIR2 is a NAD+-dependent deacety-
lase gene and a yeast homolog of the 
mammalian sirtuin family that includes 
seven SIRT proteins (Michan and Sin-
clair, 2007). SIRT1 has been shown to 
be a direct NAD+-dependent deacety-
lase for a variety of proteins, including Cancerp53, that are involved in diverse cellular 
processes such as cellular metabolism, 
extended cellular life span, and differen-
tiation (Figure 1) (Haigis and Guarente, 
2006). SIRT2 is involved in the direct 
deacetylation of α-tubulin and histone 
H4. Tenovin-6 inhibited purified mam-
malian SIRT1 and SIRT2. In cell culture 
assays, tenovin-6 treatment resulted 
in an increased acetylation of p53 at 
lysine 382, a global increase in acetyla-
tion of histone H4 at lysine 16, and ele-
vated α-tubulin acetylation. SIRT1 has 
previously been described as a potent 
negative regulator of p53 function, and 
the specific activation of p53 seen with 
Tenovin-6 underscores the importance 
of the SIRT1-p53 interaction (Luo et 
al., 2001; Vaziri et al., 2001). SIRT1 and 
SIRT2 are members of class I sirtuins, 
which includes SIRT3, but Tenovin-6 had 
limited inhibition of SIRT3. Overexpres-
sion of SIRT1 or SIRT2 weakened effects 
of tenovin-6 on p53 and α-tubulin acety-
lation, respectively, thus demonstrating 
the selectivity of this compound.
The identification and characterization 
of a compound that activates p53 without 
activation of the DNA damage response 
pathway has strong implications for both 
the development of novel chemothera-
peutics and further understanding of the 
p53 pathway. Approximately 25% of all 
human tumors retain a wild-type p53 
gene and have most likely evolved other 
cellular pathways to circumvent p53 sig-
naling (Lain and Lane, 2003). In these 
cases, use of small-molecule activators 
of p53 may attain sufficient levels of the 
protein for signaling cell growth arrest 
or apoptosis. Other compounds that  Cell 13, May 2008 ©2008 Elsevier Inc. 377
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Previewsfigure 1. Tenovins Inhibit SIRT1 and SIRT2 function
The mammalian family of sirtuins consists of seven proteins with a variety of cellular functions. Tenovins 
specifically inhibit SIRT1 and SIRT2, two specific deacetylases for several downstream substrates in-
cluding the tumor suppressor p53. Inhibition of SIRT1 and SIRT2 by tenovins at single-digit micromolar 
concentrations has a significant effect on the acetylation levels of their substrates.activate p53 through direct interaction 
(RITA) or indirectly through Mdm2 inhi-
bition (Nutlin-3A) have shown promis-
ing p53 activation and cell growth arrest 
properties in several different tumor 
cell lines tested. Compounds that spe-
cifically activate p53 through inhibition of 
upstream repressors, such as tenovins, 
may therefore be attractive chemothera-
peutics as single agents or in combina-
tion with other specific p53 activators. In 
addition to their use in cancer research, 
the identification of inhibitors of SIRT1 
and SIRT2 will be very useful for under-
standing their basic biological functions. 378 Cancer Cell 13, May 2008 ©2008 ElsevSeveral inhibitors of sirtuin deacetylase 
activity have been described, including 
sirtinol, cambinol, and EX-527, though 
none at single-digit micromolar con-
centrations similar to Tenovins (Lain et 
al., 2008). The specificity and potency 
of tenovins on SIRT1 and SIRT2 and 
the resulting activation of p53 beg the 
further analysis and characterization of 
these compounds as therapeutics for 
cancers and other diseases. Specifically, 
direct SIRT2 inhibitors have been shown 
to be effective at reducing α-synuclein-
mediated cytotoxicity in a cell-based 
Parkinson’s disease model (Outeiro et ier Inc.al., 2007). Further exploration of tenovins 
in the context of this model may be of 
particular interest for understanding the 
molecular link between sirtuins and neu-
rodegeneration. Given the success and 
limited steps needed to develop a potent, 
nongenotoxic p53 activator, mammalian 
cell-based compound screens deserve 
consideration as high-throughput read-
outs of other cell signaling pathways as 
well. The work presented by Lain et al. 
also indicates the importance of SIRT1 
in p53 activation and opens the door for 
further understanding of the biological 
functions of mammalian sirtuins.
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